ELI LILLY & Co (LLY) stock
Close on Nov 11, 2026Market cap $1.35TP/E 46.7Yield 0.43%
ELI LILLY & Co grew revenue 45.5% to $86.46B over the twelve months to Sep 30, 2026. At the latest close the market valued the company at $1.35T, 46.7 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $1.35T
- P/E ratio
- 46.7
- Price to sales
- 15.64
- Price to book
- 33.58
- Dividend yield
- 0.43%
- Free cash flow yield
- –
Fundamentals
- Revenue
- $86.46B
- Net income
- $27.58B
- EPS, diluted
- $30.81
- Book value per share
- $45.08
- Diluted shares
- 893M
Trading
- Next earnings
- Feb 3, 2027 (estimated, before the open)
- Previous close
- $1432.29
- Open
- $1418.08
- Day's range
- $1414.37 – $1440.47
- Volume
- 1,881,877
- Average volume (20 days)
- 3,070,399
- Index membership
- S&P 500, Russell 1000, Russell 3000
- Beta (5 years)
- 0.52
- 52-week range
- $850.51 – $1453.00
- RSI (14 days)
- 70.3
- Volatility (1 year)
- 35.3%
- Relative volume
- 0.72×
- WACC
- 7.4%
On 2 of our idea lists: Mega-cap growers, Superinvestor favorites
Index membership is inferred from the holdings of funds that track each index (VOO, IVV, SPYM, IWB, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2012, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | LLY | S&P 500 | Difference | LLY per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +21.9% | -2.4% | +24.3 pts | ||
| 3 months | +18.5% | -1.2% | +19.6 pts | ||
| Year to date | +34.4% | +12.3% | +22.1 pts | ||
| 1 year | +46.3% | +12.4% | +33.9 pts | ||
| 3 years | +145.5% | +78.8% | +66.7 pts | +34.9% | +21.4% |
| 5 years | +472.7% | +75.2% | +397.5 pts | +41.8% | +11.9% |
| 10 years | +2049.9% | +311.1% | +1738.8 pts | +35.9% | +15.2% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Net income
EPS, diluted
Press releases
Releases Eli Lilly filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
About Eli Lilly
Pharmaceutical Preparations
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products across a single operating segment. Its portfolio spans therapeutic treatments in cardiometabolic health, oncology, immunology, and neuroscience, addressing conditions such as diabetes, obesity, various cancers, and autoimmune disorders. The company provides its therapies to patients globally, distributing primarily through wholesale distributors, retail pharmacies, and hospitals, while engaging directly with healthcare professionals and consumers via platforms such as LillyDirect.
Company profile, executives and historyEli Lilly stock: common questions
What is Eli Lilly's stock price?
LLY closed at $1437.29 on Nov 11, 2026, up 0.35% on the day. Over the past 52 weeks it traded between $850.51 and $1453.00.
What is Eli Lilly's market cap?
Eli Lilly was worth $1.35T at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is LLY's P/E ratio?
LLY trades at 46.7 times earnings, based on diluted earnings per share of $30.81 over the twelve months to Sep 30, 2026.
How much revenue does Eli Lilly make?
Eli Lilly reported revenue of $86.46B for the twelve months to Sep 30, 2026, up 45.5% from a year earlier.
Does Eli Lilly pay a dividend?
Yes. Eli Lilly paid $6.23 per share over the last twelve months, a yield of 0.43% at the latest price, and has raised its annual dividend 9 years in a row.
When does Eli Lilly report earnings next?
Eli Lilly is expected to report Q4 FY2026 results on Feb 3, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has LLY stock performed over the past year?
Including dividends, LLY returned +46.3% over the past year, against +12.4% for the S&P 500.
How many LLY shares are sold short?
7M shares were sold short at the latest FINRA report, 0.86% of the float, or 2.7 days of average trading volume.
Who are Eli Lilly's competitors?
Companies most similar to Eli Lilly by business, industry and size include ABBV, MRK, PFE, ABT, NVO.
See a number that looks wrong?